Compare ECOR & BHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ECOR | BHM |
|---|---|---|
| Founded | 2005 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.0M | 40.6M |
| IPO Year | 2018 | 2022 |
| Metric | ECOR | BHM |
|---|---|---|
| Price | $6.25 | $10.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $18.00 | $15.00 |
| AVG Volume (30 Days) | ★ 67.0K | 9.7K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.44% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $32,032,000.00 | ★ $68,734,000.00 |
| Revenue This Year | $33.60 | N/A |
| Revenue Next Year | $30.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 27.20 | ★ 36.88 |
| 52 Week Low | $4.16 | $8.05 |
| 52 Week High | $8.55 | $14.81 |
| Indicator | ECOR | BHM |
|---|---|---|
| Relative Strength Index (RSI) | 49.40 | 51.33 |
| Support Level | $4.65 | $10.90 |
| Resistance Level | $6.94 | $12.11 |
| Average True Range (ATR) | 0.65 | 0.71 |
| MACD | 0.04 | -0.07 |
| Stochastic Oscillator | 46.45 | 37.39 |
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
Bluerock Homes Trust Inc owns and operates a portfolio of institutional residential properties including single-family homes, build-to-rent communities, and other residential communities located in attractive markets with a focus on the knowledge-economy and high-quality of life growth markets of the Sunbelt and Western United States. The company's principal objective is to generate attractive risk-adjusted returns on investments where it believes it can drive growth in funds from operations and net asset value by acquiring residential units, developing residential communities, and through value-add renovations. The company has two reportable segments, consisting of Residential Communities, which derives maximum revenue; and Scattered Single-family homes.